Fellay et al. first demonstrated that genetic variants leading to inosine triphosphatase deficiency protect against haemolytic anaemia in chronic hepatitis C patients treated with ribavirin (RBV)47. This evidence concerns the gene ITPA and chronic hepatitis C virus infection.